10x Genomics, Inc. (TXG) [Rocket]

In millions, except per share items	Mar-31-23	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21	Dec-31-20
	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K
Revenue		497.9	499.2	490.5	459.2	405.7	332.8	298.8
Revenue growth		22.7%	50.0%	64.1%	75.3%	61.4%	25.9%	21.5%
Cost of revenue		105.3	82.5	74.1	65.4	55.3	60.4	58.5
Gross profit		392.6	416.7	416.4	393.8	350.4	272.3	240.4
Gross margin		78.9%	83.5%	84.9%	85.8%	86.4%	81.8%	80.4%

Operating expenses:
Research and development		251.2	233.9	211.8	189.6	165.1	139.3	123.4
Selling, general and administrative		278.0	267.3	257.6	243.7	233.1	208.8	202.3
Total operating expenses		661.0	754.3	722.5	961.9	967.9	796.8	774.5
Loss from operations		-136.6	-83.8	-52.3	-446.0	-495.4	-524.5	-534.1
Operating margin		-27.4%	-16.8%	-10.7%	-97.1%	-122.1%	-157.6%	-178.7%

Other income (expense):
Interest income		1.9	0.7	0.2	0.2	0.2	0.3	1.5
Interest expense		-0.7	-0.8	-0.9	-1.0	-1.1	-1.2	-1.7
Other expense, net		-2.8	-0.5	-0.8	0.4	1.4	0.7	1.3
Total other income		-3.8	-0.4	-0.9	1.5	2.6	1.4	1.4
Loss before provision for income taxes		-138.2	-84.3	-53.7	-446.3	-495.0	-524.7	-534.5
Provision for income taxes		4.3	4.8	4.5	9.0	9.1	8.4	8.3
Net loss		-142.5	-89.1	-58.2	-455.3	-504.0	-533.1	-542.7

Net loss per share, basic (in dollars per share)		($1.27)	($0.80)	($0.53)	($4.45)	($4.95)	($5.26)	($5.37)
Net loss per share, diluted (in dollars per share)		($1.27)	($0.80)	($0.53)	($4.45)	($4.95)	($5.26)	($5.37)

Weighted-average shares of common stock used in computing net loss per share, basic		111.9	111.0	110.0	107.7	105.3	102.5	99.6
Weighted-average shares of common stock used in computing net loss per share, diluted		111.9	111.0	110.0	107.7	105.3	102.5	99.6